T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.
Research led by Dr. Wonmuk Hwang has led to a better understanding of how components of the body's immune system find intruding or damaged cells, which could lead to novel approaches to viral and cancer treatments.
Methicillin-resistant Staphylococcus aureus (MRSA) is the most lethal drug-resistant bacteria and is also one of the most common bacterial pathogens.
Physicians at City of Hope, working in collaboration with scientists at Translational Genomics Research Institute (TGen), have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on Food and Drug Administration-approved immunotherapy regimens.
Investigators led by a team at Massachusetts General Hospital (MGH) have made discoveries at the single cell level to uncover new details concerning mitochondrial diseases-- inherited disorders that interfere with energy production in the body and currently have no cure.
A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.
Scientists at The Wistar Institute may have discovered a new way of identifying and targeting hidden HIV viral reservoirs during treatment with antiretroviral therapy (ART).
Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer.
In order for cancer to form in the human body, normal cells must acquire multiple mutations before they develop toward the disease. It was previously believed that these mutations acted in concert in the progression of cancer.
Within the immune system, the T lymphocytes operate to kill cancer cells or infected cells.
The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics spin-off, the aim of which is to develop new immuno-oncological therapeutic tools with various preclinical candidates, based on CAR-T technology for different tumors, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), a rare subtype of leukemia that mainly affects children, and which has a poor prognosis.
According to a study, researchers have successfully designed natural killer immune cells that destroy head and neck tumor cells in mice.
A method known as CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.
AZoLifeSciences speaks to Professor David J. Rawlings from the Seattle children's hospital about recent developments in engineered T cells for type 1 diabetes.
House dust mites can be found everywhere around the world. When individuals do some cleaning work, they will probably stir up some of these dust mites.
In the fight against cancer or chronic infections, the immune system must be active over long periods of time.
MicroRNAs, are attracting interest relating to human diseases because variations in the expression of miRNAs are often associated with abnormal functions.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute has identified a protein within certain immune cells that is required for optimal immune responses to cancer.
Dendritic cells are one of our bodies' first line of defense and are stationed like sentinels at all surfaces, as well as in most of our organs.
Acute myeloid leukemia is an aggressive cancer of the blood-forming system. It affects the hematopoietic stem cells, or blood stem cells, of various white blood cells and of the red blood cells and platelets.
A team in Massachusetts has established a method of profiling of mispairing in antibody assembly.